Latest Incyte Corporation Stories
INDIANAPOLIS and WILMINGTON, Del., Dec.
RESEARCH TRIANGLE PARK, N.C., May 19 /PRNewswire/ -- ArtusLabs, Inc. (www.artuslabs.com), the leader in scientifically-aware data management systems, today announced a collaborative license agreement with Incyte Corporation to address two prevalent industry problems.
Incyte Corporation (Nasdaq:INCY) announced today the presentation of clinical results from a 28-day Phase IIa trial of INCB18424, its orally available janus kinase (JAK) inhibitor, in patients with rheumatoid arthritis (RA).
Incyte Corporation (Nasdaq:INCY) reported positive results from two 28-day Phase IIa clinical trials of topical INCB18424, a selective janus-associated kinase (JAK) inhibitor, in patients with mild to moderate psoriasis.
Incyte Corporation (Nasdaq:INCY) today announced its second quarter 2008 financial results and reported continued progress in several lead clinical programs.
- In dressmaking, straps running from the belt in front over the shoulders to the belt in the back, with more or less elaboration of trimming and outline. They usually broaden at the shoulder and narrow toward the waist.